Rheumatic Heart Disease Market Report 2026

The rheumatic heart disease market size has grown strongly in recent years. It will grow from $2.71 billion in 2025 to $2.88 billion in 2026 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to high prevalence of untreated streptococcal infections, limited access to early healthcare in developing regions, historical burden of rheumatic fever, dependence on clinical diagnosis methods, constrained availability of advanced cardiac care.

The rheumatic heart disease market size is expected to see strong growth in the next few years. It will grow to $3.6 billion in 2030 at a compound annual growth rate (CAGR) of 5.8%. The growth in the forecast period can be attributed to increasing investments in public health screening programs, rising adoption of digital cardiac diagnostics, growing awareness of early intervention benefits, expansion of cardiac surgical infrastructure, increased focus on disease prevention strategies. Major trends in the forecast period include increasing adoption of early diagnostic screening programs, rising use of echocardiography and imaging tools, growing focus on preventive antibiotic therapies, expansion of valve repair and replacement procedures, enhanced monitoring of pediatric and adolescent patients.

The rising prevalence of strep throat is anticipated to drive the growth of the rheumatic heart disease market in the coming years. Strep throat is a bacterial infection caused by Streptococcus pyogenes (group A streptococcus) that leads to throat inflammation and pain, often accompanied by fever, swollen lymph nodes, and difficulty swallowing. Increasing antibiotic resistance is making streptococcal infections more difficult to treat effectively, resulting in prolonged illness and higher transmission rates within communities. Rheumatic heart disease develops as a long-term complication of untreated or recurrent strep throat infections, underscoring the critical importance of early diagnosis and timely treatment of streptococcal infections to prevent severe and irreversible cardiac damage. For example, in April 2023, according to the Centers for Disease Control and Prevention, a US-based government agency, strep throat accounted for an estimated 5.2 million outpatient visits annually among individuals under 65 years of age, leading to approximately 2.8 million antibiotic prescriptions each year. Therefore, the increasing prevalence of strep throat is fueling the growth of the rheumatic heart disease market.

Major companies and organizations operating in the rheumatic heart disease market are increasingly adopting strategic partnerships to develop innovative diagnostic and treatment solutions. Strategic collaborations in rheumatic heart disease management combine resources, technical expertise, and global reach to accelerate research and development, improve early detection and therapeutic approaches, expand access to care, and speed up the adoption of new solutions. For instance, in July 2023, the World Heart Federation (WHF), a Switzerland-based non-governmental organization, partnered with the Philips Foundation, a Netherlands-based nonprofit organization, to enhance awareness, clinical training, and early detection of rheumatic heart disease in the Asia-Pacific region. Launched in the Philippines, this initiative aims to improve healthcare access for more than half a million at-risk children by equipping healthcare facilities with trained professionals and advanced diagnostic tools, reflecting a shared commitment to strengthening healthcare infrastructure and enabling timely intervention for RHD patients.

In February 2025, Light AI Inc., a Canada-based healthcare technology company, partnered with MrBeast Industries to support global health initiatives focused on infectious disease prevention. Through this collaboration, AI-powered Strep A diagnostic tests are being donated across Africa to enable early detection and treatment of streptococcal infections, thereby reducing the risk of severe complications such as rheumatic heart disease. MrBeast Industries is a US-based media and entertainment company specializing in digital content creation and philanthropic initiatives.

Major companies operating in the rheumatic heart disease market are Pfizer Inc., Merck And Co Inc., Bayer AG, Sanofi SA, AstraZeneca plc, Novartis AG, Abbott Laboratories, GlaxoSmithKline plc, Medtronic plc, Siemens Healthineers AG, Becton Dickinson And Company, GE HealthCare Technologies Inc., Boston Scientific Corporation, Terumo Corporation, Apollo Hospitals Enterprise Limited, Fortis Healthcare Limited, Medanta, Johnson And Johnson Services Inc., Roche Holding AG, Bristol Myers Squibb Company, Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company, Boehringer Ingelheim International GmbH, Edwards Lifesciences Corporation.

North America was the largest region in the rheumatic heart disease market in 2025. The regions covered in the rheumatic heart disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the rheumatic heart disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the rheumatic heart disease market by increasing costs of imported diagnostic imaging equipment, surgical instruments, prosthetic heart valves, and pharmaceutical raw materials used in treatment and management. Hospitals and cardiac care centers in low- and middle-income regions are most affected due to reliance on imported medical devices, while developed regions face higher procedural costs. These tariffs can delay equipment procurement and increase treatment expenses. However, they are also encouraging local manufacturing of medical devices, regional sourcing of pharmaceuticals, and improved self-sufficiency in cardiac care infrastructure.

The rheumatic heart disease market research report is one of a series of new reports that provides rheumatic heart disease market statistics, including rheumatic heart disease industry global market size, regional shares, competitors with a rheumatic heart disease market share, detailed rheumatic heart disease market segments, market trends and opportunities, and any further data you may need to thrive in the rheumatic heart disease industry. This rheumatic heart disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Rheumatic heart disease (RHD) is a long-term heart condition caused by permanent damage to the heart valves following rheumatic fever, an inflammatory illness that results from untreated or inadequately treated streptococcal throat infections. The immune response to the infection leads to inflammation and scarring of the heart valves, which impairs their function and may result in heart failure, arrhythmias, or other serious complications.

The main types of rheumatic heart disease include valve-related disease, myocarditis, and pericarditis. Valve-related rheumatic heart disease develops when rheumatic fever damages the heart valves, causing disrupted blood flow and complications such as stenosis or regurgitation. The affected age groups include pediatric, adolescent, adult, and geriatric populations. Rheumatic heart disease is diagnosed and treated across various settings, including hospitals, diagnostic centers, and research centers. Drug distribution channels include hospital pharmacies, retail pharmacies, online pharmacies, and direct sales.

The rheumatic heart disease market consists of revenues earned by entities by providing services such as surgical treatments, diagnostic tests, preventive care services, and pediatric care services. The market value includes the value of related goods sold by the service provider or included within the service offering. The rheumatic heart disease market also includes sales of antibiotics, anti-inflammatory medications, diuretics, beta-blockers, and ACE inhibitors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.